Rinomaris spray naz. 0.5mg/ml 15ml №1

Name:
Rinomaris spray naz. 0.05% in vial 15ml in pack. No. 1
Description:
Colorless, odorless, transparent solution Main active ingredient Xylometazoline Release form Dosed nasal spray Dosage 0.05% in vial. 15 ml Special instructions Before use, clean the nasal passages (blow your nose). Before the first use, press the spray valve several times until a dispersed spray appears. Pharmacological properties Pharmacodynamics Rinomaris is a drug for intranasal use. Xylometazoline has an alpha-adrenomimetic effect: it causes constriction of the blood vessels of the nasal mucosa, thus eliminating swelling and hyperemia of the nasopharyngeal mucosa. Facilitates nasal breathing in rhinitis. In therapeutic concentrations, it does not irritate the mucous membrane, does not cause hyperemia, and does not disrupt the function of the ciliated epithelium. The action usually occurs within 5-10 minutes after application and lasts for 12 hours. Pharmacokinetics When applied topically, it is practically not absorbed, plasma concentrations are so small that they cannot be determined by modern analytical methods. Indications for use Acute respiratory diseases with symptoms of rhinitis (runny nose), allergic rhinitis, hay fever, sinusitis, otitis media (to reduce swelling of the nasopharyngeal mucosa). Preparation of the patient for diagnostic manipulations in the nasal passages. Dosage and administration Children aged 2 to 12 years: 1 injection in each nostril up to 3 times a day; In children from 1 to 2 years old, the drug is used only as prescribed by the doctor and according to his prescriptions. In children from 2 to 12 years of age, the drug should be used only under adult supervision. Precautions Rinomaris should be used with caution in patients with: high blood pressure, cardiovascular disease, hyperthyroidism, diabetes mellitus, pheochromocytoma, prostatic hypertrophy, taking monoamine oxidase inhibitors (MAOIs) within 14 days prior to the start of Rinomaris (see. section “Drug Interactions”) with hypersensitivity to sympathomimetics, which may manifest symptoms such as insomnia, dizziness, etc. Do not use Rinomaris for more than 7 days in a row, as this can lead to the development of drug-induced rhinitis, manifested by increased secretion of mucus and edema nasal mucosa. Recommended doses should not be exceeded, especially in children and elderly patients. Rinomaris nasal spray 0.05% is not intended for use in children under 1 year of age. In children from 1 to 2 years old, the drug is used only as prescribed by the doctor and according to his prescriptions. In children from 2 to 12 years of age, the drug should be used only under adult supervision. Pregnancy and lactation Due to the vasoconstrictive effect of Rinomaris, it should not be used during pregnancy. The use of the drug during lactation is possible only on prescription. Influence on the ability to drive vehicles and control mechanisms Xylometazoline in doses exceeding those recommended may affect the ability to drive vehicles or equipment. Interaction with other drugs MAO inhibitors: xylometazoline can enhance the effect of MAO inhibitors, which can lead to the development of a hypertensive crisis. Rinomaris should be used with caution in patients who have taken MAO inhibitors within 14 days prior to the start of Rinomaris. Tri- or tetracyclic antidepressants: The simultaneous use of tri- or tetracyclic antidepressants may lead to an increase in the sympathomimetic effect of xylometazoline and is therefore not recommended. Contraindications Dry rhinitis, atrophic rhinitis, glaucoma, transsphenoidal hypophysectomy, surgical interventions on the meninges (history), hypersensitivity to the components of the drug. Ingredients in mg per 1 ml of the drug Active ingredient Xylometazoline hydrochloride 0.500 Excipients Adriatic Sea water 251.000 Potassium dihydrogen phosphate 0.502 Purified water 751.996 , to the development of hypertension or hypotension, tachycardia or bradycardia. Nausea, vomiting, and other symptoms may occur, including pallor, excessive sweating, fever, miosis, respiratory failure, ataxia, and restlessness. In young children, the use of xylometazoline at a dosage of up to 0.5 mg / kg of body weight does not lead to the development of clinically significant symptoms. Above a dosage of 0.5 mg/kg body weight, serious symptoms cannot be ruled out, although sufficient supporting data have not yet been collected. There is no specific antidote for overdose. Treatment: symptomatic therapy, the appointment of atropine for bradycardia. Side effect From the side of the immune system: Very rarely (<1/10000): hypersensitivity reactions (angioneurotic edema, rash, itching). From the side of the nervous system: Often (≥1/100, <1/10): headache. On the part of the organ of vision: Very rarely (<1/10000): temporary visual impairment. From the cardiovascular system: Very rarely (<1/10000): palpitations, hypertension, arrhythmia From the respiratory system: Often (?1/100, <1/10): dryness, burning of the nasal mucosa, drug-induced rhinitis. From the gastrointestinal tract: Often (≥1/100, <1/10): nausea. Other: Often (?1/100, <1/10): burning sensation at the site of application. If the listed adverse reactions occur, as well as reactions not listed in the instructions for medical use, you should consult a doctor. Storage conditions Store at a temperature not exceeding 25 ° C, out of the reach of children. Buy Rinomaris spray naz. 0.5mg/ml 15ml №1 Price for Rinomaris spray called. 0.5mg/ml 15ml №1 Instructions for use for Rinomaris spray naz. 0.5mg/ml 15ml №1